. intolerance). Ibrutinib is The existing gold conventional therapy for individuals with relapsed/refractory disease, according to the outcome of many phase I-III trials, one hundred fifteen–119 but this is also altering for two principal explanations: (i) an increasing proportion of people currently get ibrutinib as frontline therapy; and (ii) some https://calebi318gov7.wikicommunication.com/user